+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
MyoKardia Inc - logo

MyoKardia is a clinical stage biopharmaceutical company that develops therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

From
From
Hypertrophic Cardiomyopathy - Pipeline Insight, 2022 - Product Thumbnail Image

Hypertrophic Cardiomyopathy - Pipeline Insight, 2022

  • Clinical Trials
  • May 2022
  • 60 Pages
From
From
Dilated Cardiomyopathy - Pipeline Insight, 2020 - Product Thumbnail Image

Dilated Cardiomyopathy - Pipeline Insight, 2020

  • Clinical Trials
  • September 2020
  • 67 Pages
From
Cardiomyopathy Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Cardiomyopathy Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • December 2018
  • 247 Pages
From
From
Hypertrophic Cardiomyopathy - Pipeline Review, H2 2020 - Product Thumbnail Image

Hypertrophic Cardiomyopathy - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 102 Pages
From
Atrial Fibrillation - Pipeline Review, H2 2020 - Product Thumbnail Image

Atrial Fibrillation - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 134 Pages
From
From
From
From
From
Loading Indicator